Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyclophosphamide vs ATG with Cyclosporine in Severe Aplastic Anemia
NCT00001626Phase 2Completed
- Sponsor
- National Heart, Lung, and Blood Institute
- Start
- Jun 1997
- Primary completion
- Feb 2001
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cyclophosphamide in aplastic anemia (2 arms), sponsored by National Heart, Lung, and Blood Institute. Primary endpoint: Sustained Response Proportions at 12 weeks. Started Jun 1997; status: completed.
02
Drugs
cyclophosphamide
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on NCT00001626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00001626.